S&P 500
5.180,74 +52,95 (+1,03%) Nasdaq
16.349,25 +192,92 (+1,19%) NIKKEI 225
38.766,36 +530,29 (+1,39%) Dólar/Euro
1,0772 -0,0001 (-0,01%) Petróleo Brent
83,54 +0,21 (+0,25%) Bitcoin EUR
58.767,23 -522,61 (-0,88%)
DexCom, Inc. (DXCM)
Después del cierre:
DexCom, Inc.
6340 Sequence Drive
San Diego, CA 92121
United States
858 200 0200
https://www.dexcom.com
Sector(es): Healthcare
Sector: Medical Devices
Empleados a tiempo completo: 9500
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Kevin Ronald Sayer | Executive Chairman, CEO & President | 3,23M | N/A | 1958 |
| Mr. Jereme M. Sylvain | Executive VP, CFO & Chief Accounting Officer | 1,13M | N/A | 1980 |
| Mr. Jacob Steven Leach | Executive VP & COO | 1,29M | N/A | 1978 |
| Mr. Michael Jon Brown | Executive VP & Chief Legal Officer | 1,22M | N/A | 1970 |
| Ms. Teri Lawver | Executive VP & Chief Commercial Officer | 1,41M | N/A | 1967 |
| Mr. Girish Naganathan | Executive VP & CTO | 423,92k | N/A | 1977 |
| Mr. Shelly Ramasamy Selvaraj | Senior VP & Chief Information Officer | N/A | N/A | 1959 |
| Mr. Sean Christensen | Director of Corporate Affairs & Head of Investor Relations | N/A | N/A | N/A |
| Mr. Matthew Dolan | Executive Vice President of Strategy, Corporate Development & Dexcom Labs | N/A | N/A | 1981 |
| Ms. Leverne Marsh | Executive Vice President of Marketing | N/A | N/A | N/A |
Descripción
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Gobierno corporativo
El ISS Governance QualityScore de DexCom, Inc., a día 1 de mayo de 2024, es 5. Las puntuaciones base son Auditoría: 2; Tablero: 9; Derechos de los accionistas: 6; Compensación: 2.
